Rubicon Genomics Licenses Commercialization Rights From SomaGenics for Its RealSeq®-AC Technology for High-Throughput Sequencing of Small RNA's
SANTA CRUZ, Calif., July 28, 2016 /PRNewswire/ -- SomaGenics Inc. today announced that it has signed a licensing agreement with Rubicon Genomics, Inc. for commercialization of SomaGenics' RealSeq®-AC library preparation technology for sequencing small RNAs, including micro-RNAs and small fragments of large RNAs. Further terms of the agreement were not disclosed.
The RealSeq®-AC platform is a novel technology that dramatically reduces sequencing bias compared to standard methods for preparing libraries for small RNA sequencing. RealSeq®-AC allows detection and discovery of many small RNAs that are often underestimated by up to 104-fold of their true abundance.
"We are excited to commercialize our RealSeq®-AC technology with Rubicon Genomics, given their impressive product portfolio and market position in the area of next generation sequencing sample preparation," said Brian Johnston, Ph.D., President and CEO of SomaGenics.
Rubicon Genomics is a leading worldwide provider of pre-analytical library preparation kits that increase the accuracy, efficiency and speed of genomic analysis. It offers a diverse product line including ThruPLEX® DNA-seq kits, ThruPLEX® Plasma-seq kits, PicoPLEX® DNA-seq and WGA kits and TransPLEX® C-WTA kits.
Rubicon CEO James Koziarz, Ph.D., commented, "We are very pleased to add SomaGenics' technology to Rubicon's proprietary suite of products as they nicely complement and expand our RNA offerings. We currently sell TransPLEX kits as a component of Agendia's FDA-cleared MammaPrint® breast cancer assay and ThruPLEX® through our OEM relationship with Clontech for their RNA-seq Low Input Library Prep kit. The RealSeq®-AC technology allows us to further expand our RNA library preparation line with a product that offers performance superior to existing technologies. SomaGenics' exceptional development work on the technology will enable our product development and commercialization teams to move towards a smooth and timely launch."
About SomaGenics, Inc. SomaGenics, Inc. is a privately held biotech company located in Santa Cruz, California. It specializes in developing innovative technologies that focus on RNA as therapeutic agents, targets and biomarkers as well as on RNA research and molecular diagnostic tools. Besides Real-Seq®-AC, the company's technologies include miR-ID® and miR-Direct®, novel circularization-based RT-qPCR methods for small RNA detection; ResQ™, a method for quantifying fragmented RNA from FFPE samples; and short synthetic hairpin RNA-based therapeutic candidates for wound healing and hepatitis delta virus (HDV). For more information visit somagenics.com.
About Rubicon Genomics, Inc.
Rubicon Genomics develops innovative, high quality, nucleic acid library preparation and companion products for research applications that enable easy, reliable, and highly sensitive analysis of samples. Rubicon is committed to teamwork and continuous improvement to provide excellence to our customers, shareholders, and employees. Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit rubicongenomics.com.
SomaGenics Contact: Anne Scholz, Head, Business Development, Email (831-426-7700 x20)
Rubicon Genomics Contact: Jamie Wibbenmeyer, VP Business Development, Email
SOURCE SomaGenics, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article